Latest News
Linnaeus Therapeutics Granted Orphan Drug Designation for LNS8801 for the Treatment of Patients with Metastatic Cutaneous Melanoma
Linnaeus Therapeutics Granted Orphan Drug Designation for LNS8801 for the Treatment of Patients with Metastatic Cutaneous Melanoma Haddonfield NJ, January 19, 2023--Linnaeus Therapeutics, Inc. (Linnaeus), a privately [...]
Linnaeus Therapeutics Announces Issuance of Patent for LNS8801 by the U.S. Patent and Trademark Office
Linnaeus Therapeutics Announces Issuance of Patent for LNS8801 by the U.S. Patent and Trademark Office Haddonfield NJ, September 21, 2022 - Linnaeus Therapeutics, Inc. (Linnaeus), a [...]
Linnaeus Therapeutics Announces Presentation of LNS8801 Clinical Data at 2022 ESMO Annual Meeting
Linnaeus Therapeutics Announces Presentation of LNS8801 Clinical Data at 2022 ESMO Annual Meeting Haddonfield NJ, September 12, 2022 - Linnaeus Therapeutics, Inc. (Linnaeus), a privately held clinical-stage [...]
Linnaeus Therapeutics Announces Presentation of Positive Clinical Data of LNS8801 at 2022 ASCO Annual Meeting
Linnaeus Therapeutics Announces Presentation of Positive Clinical Data of LNS8801 at 2022 ASCO Annual Meeting Haddonfield NJ, June 6, 2022 -- Linnaeus Therapeutics, Inc. (Linnaeus), a [...]
Linnaeus Therapeutics Awarded $4,000,000 SBIR Phase 2 Bridge Award by the National Cancer Institute to Advance LNS8801 for the Treatment of Cutaneous and Uveal Melanoma
Linnaeus Therapeutics Awarded $4,000,000 SBIR Phase 2 Bridge Award by the National Cancer Institute to Advance LNS8801 for the Treatment of Cutaneous and Uveal Melanoma Haddonfield [...]
Linnaeus Therapeutics Announces Expanded Clinical Collaboration with Merck to Include Multiple Additional Cohorts to Evaluate LNS8801 in Combination with KEYTRUDA® in Patients with Advanced Cancer
Linnaeus Therapeutics Announces Expanded Clinical Collaboration with Merck to Include Multiple Additional Cohorts to Evaluate LNS8801 in Combination with KEYTRUDA® in Patients with Advanced Cancer Studies Will [...]
We Listen to the Clinical Experience
We allow it to inform the science that drives the development of new treatments to treat cancer.